Monashee Investment Management LLC Buys New Position in ImageneBio, Inc. $IMA

Monashee Investment Management LLC bought a new stake in ImageneBio, Inc. (NASDAQ:IMA) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 91,621 shares of the company’s stock, valued at approximately $632,000.

A number of other large investors have also recently made changes to their positions in IMA. Goldman Sachs Group Inc. boosted its position in shares of ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after purchasing an additional 29,369 shares during the period. Vanguard Group Inc. acquired a new stake in shares of ImageneBio in the 3rd quarter valued at about $1,902,000. BML Capital Management LLC acquired a new stake in shares of ImageneBio in the 3rd quarter valued at about $1,487,000. Aldebaran Capital LLC acquired a new stake in shares of ImageneBio in the 3rd quarter valued at about $159,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio in the 3rd quarter valued at about $4,409,000. 75.00% of the stock is owned by institutional investors and hedge funds.

ImageneBio Trading Up 3.6%

ImageneBio stock opened at $5.71 on Friday. ImageneBio, Inc. has a twelve month low of $3.94 and a twelve month high of $18.00. The stock has a 50 day moving average of $5.58 and a two-hundred day moving average of $6.17. The stock has a market capitalization of $60.83 million, a price-to-earnings ratio of -0.99 and a beta of 0.72.

ImageneBio (NASDAQ:IMA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.25). Equities analysts predict that ImageneBio, Inc. will post -3.66 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on IMA. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, ImageneBio has a consensus rating of “Hold” and an average target price of $26.50.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.